What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

The move is the latest recruiting win for RBC Wealth Management as it continues to lure top talent away from big banks and ...

Boss also lowered his FY gross margin to 58.8%, representing a 70-basis point decline year-over-year, attributed to headwinds ...

J.P. Morgan analyst Ranjan Sharma maintained a Buy rating on Grab (GRAB – Research Report) on January 21 and set a price target of $5.60. The ...

Jamie Dimon, chairman and CEO, noted in the release that in the asset and wealth management division client net inflows ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

J.P. Morgan Healthcare Conference is officially underway, bringing the healthcare and biopharma industries' biggest wheelers ...

The Westin St. Francis Hotel in Union Square will once again be host for one of the biggest conventions in the city--the J.P.

Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the ...

J.P. Morgan analyst Mark Strouse maintained a Hold rating on Bloom Energy (BE – Research Report) yesterday and set a price target of $16.00.

Investing.com -- J.P. Morgan analysts have upgraded their rating for Aviva plc (LON: AV) to "overweight" from "neutral," ...